Algeta announced it has been awarded a $1.9 million grant from the Research Council of Norway to develop targeted thorium conjugates (TTCs), novel tumor-targeted alpha-pharmaceuticals based on thorium-227.
Novartis said an advisory panel recommended against approving a potential treatment for the inflammatory disease gouty arthritis because they were concerned about the drug's safety.
Naurex Inc. has initiated a Phase 2 clinical trial of its lead compound GLYX-13.
Because automation is highly desired by researchers, LabStrong Corporation has added their automated AccuStop technology to their revolutionary Helix 250 Orbital Shaker.
INTEGRA has released a new application note that demonstrates how combining its MEDIAJET Petri dish filler with the DOSE IT peristaltic pump provides an optimised automated solution for the production of high quality blood agar.
CiToxLAB, created through the merger of CIT and LAB Research, provides a comprehensive range of pre-clinical and specialty services from four facilities in France, Canada, Denmark, and Hungary.
The recent nuclear crisis in Japan has highlighted the urgent need to develop products for the treatment of acute radiation sickness and radiation exposure.
Drugmaker Pfizer Inc. said that early results from a late-stage study of its pain treatment Lyrica showed that it did better than a placebo in reducing one type of pain after a spinal cord injury.
The Food and Drug Administration has issued a warning letter to CSL Biotherapies over its manufacturing facilities for the influenza vaccine, Afluria, which it sells in the US.
Abbott Laboratories said that it will pay German company Biotest AG $85 million upfront and royalty and milestone payments that could total $395 million as part of a collaboration over a potential rheumatoid arthritis and psoriasis treatment.
AstraZeneca PLC is selling its Astra Tech dental business, the world's third-largest maker of dental implants, for $1.8 billion, the Anglo-Swedish pharmaceutical company announced.
Novartis AG said an advisory panel recommended against approving a potential treatment for the inflammatory disease gouty arthritis because they were concerned about the drug's safety.
The U.S. Food and Drug Administration (FDA) has unveiled a strategy to meet the challenges posed by imports of FDA-regulated products and a complex global supply chain.
LifeCycle Pharma reported the company’s lead product candidate, LCP-Tacro, successfully demonstrated non-inferiority compared to tacrolimus (Prograf from Astellas Pharma) in its Phase III trial, Study 3001.
Findings from three studies conducted by the U.S. Food and Drug Administration (FDA) confirm that the way information is conveyed and displayed in printed drug advertising affects consumer understanding of prescription medications.